Pipeline

Using its proprietary CAR platform, Leucid has developed a pipeline of assets for the treatment of solid tumours and haematological malignancies.

Category

Programme

Preclinical

IND Submission

Phase 1/2

Product

Solid Tumours

LEU-001

Autologous CAR T cells

T4 (SCCHN)

Phase 1/2

LEU-002

Autologous CAR T cells

IND Submission

LEU-005

Allogenic CAR T cells

Preclinical Development

Haematological
Malignancies

LEU-004

LEU-006

Autologous CAR T cells

IND Submission

Allogenic CAR T cells

Preclinical Development